Cybin Reports First Quarter Financial Results and Recent Business Highlights

“The steady clinical progress we have made over the past few months is truly encouraging, with dosing initiated in the final cohort of our Phase 2 CYB003 MDD study and CYB004 dosing underway in Part C of our Phase 1 CYB004-E study. We expect topline data for our CYB003 and CYB004 programs later this year, which we anticipate will provide insights into the therapeutic profile of our deuterated molecules as potentially differentiated treatments for mental health conditions. The recent marketed public offering further strengthens our position to deliver on these value-driving milestones. I am proud of the Cybin team’s thoughtful approach and strategic decisions that have enabled us to accelerate our clinical-stage programs. We look to build on this momentum as we advance to future pivotal studies, with work already underway in developing a scalable version of our EMBARK psychedelic facilitation program and through our partnership with Worldwide Clinical Trials, a global contract research organization.”

Doug Drysdale, Chief Executive Officer of Cybin

• Initiated dosing in Cohort 6, the final cohort of the Phase 2 study of CYB003 in Major Depressive Disorder (“MDD”), following the successful completion of Cohort 5. To date, CYB003, a deuterated psilocybin analog, has been shown to have a favorable safety and tolerability profile at doses of up to 12mg based on the five completed cohorts, with no serious adverse events or discontinuations due to adverse events. Further, CYB003 has demonstrated a robust psychedelic response at multiple dose levels. CYB003’s therapeutic profile as a potentially differentiated treatment for MDD has the potential to provide consistent and predictable dosing, with the goal of delivering a rapid and robust treatment response at low dose levels.
• Announced a partnership with Worldwide Clinical Trials (“Worldwide”) to support the future clinical development and regulatory strategy for CYB003 in MDD. Worldwide is a global, full-service CRO and was selected by the Company for its deep expertise managing clinical trials for mental health conditions including MDD and its track record supporting industry-sponsored psychedelic studies. The Company’s collaboration with Worldwide has played a pivotal role to date in the development of study designs, navigating regulatory pathways, and defining global regulatory strategy.
• Announced the development of EMBARK^CT, a scalable psychedelic facilitation training program, to support larger pivotal studies. EMBARK^CT is designed to allow the Company to effectively screen, qualify, and train facilitators to provide support and in-person monitoring for participants in larger pivotal trials of the Company’s investigational therapeutics. The evolution of the EMBARK training program to EMBARK^CT is expected to enhance the scalability of the Company’s facilitator training, enabling high-quality psychedelic facilitation suitable for a multisite, global clinical trial. To date, approximately 1,500 individuals have enrolled in EMBARK Open Access, the Company’s free online introduction to psychedelic facilitator training.
• Continued to advance its Phase 1 CYB004-E study, with CYB004 dosing underway in Part C, the final portion of the study. Data from the Phase 1 study is expected to inform optimal dosing for future clinical trials of CYB004, a proprietary deuterated dimethyltryptamine (“dDMT”) molecule being developed for the potential treatment of generalized anxiety disorder (“GAD”). In healthy subjects, CYB004 appears to provide a rapid onset of psychedelic effects within 2 minutes and peak effects at around 12 minutes after dosing. The Company is targeting a scalable psychedelic treatment duration of 45-60 minutes.
• Announced the publication of results of the Cybin-sponsored Flow Kernel feasibility study. The results, which were published in the journal Scientific Reports from the Nature Portfolio of Journals, demonstrate the Flow1 neuroimaging system’s ability to measure acute changes in functional brain activity during the administration of a psychedelic compound.
• Closed a US$8.25 million marketed public offering to support the clinical development of the Company’s CYB003 and CYB004 programs.

• Completion of CYB003 dosing in MDD cohorts expected in Q3 2023.
• Phase 2 topline efficacy data expected in Q3/Q4 2023.
• FDA submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023.

• Phase 1 topline data readout, including safety, dosing, and pharmacokinetic and pharmacodynamic data, expected in Q3/Q4 2023.

• Cash totaled C$9.3 million as of June 30, 2023, and C$18.0 million as of August 14, 2023.
• Net loss was C$14.5 million for the quarter ended June 30, 2023, compared to a net loss of C$13.1 million in the same period last year.
• Operating expenses totaled C$12.7 million for the quarter ended June 30, 2023, compared to C$13.4 million in the same period last year, which includes a non-cash component related to share-based compensation of C$1.3 million compared to C$2.2 million for the respective periods.
• Cash flows used in operating activities were C$10.7 million for the quarter ended June 30, 2023, compared to C$11.1 million in the same period last year.
• Cash flows received from financing activities were C$3.5 million for the quarter ended June 30, 2023, related to the net proceeds on the issuance of common shares through the Company’s at-the-market equity program and the common share purchase agreement with Lincoln Park Capital Fund, LLC.